SCHEMBL17686362

SCHEMBL17686362

CCCCCCCCCC(O)C(F)(F)C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.43
SPHK1 Q9NYA1 2/20 0.43
FFAR1 O14842 2/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.42
CYP2D6 P10635 2/20 0.41
GMNN O75496 1/20 0.41
POLB P06746 1/20 0.41
THPO P40225 1/20 0.41
MTOR P42345 1/20 0.41
BLM P54132 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CETP P11597 1/20 0.41
HTT P42858 1/20 0.41
UBE2N P61088 1/20 0.41
FFAR4 Q5NUL3 1/20 0.39
FAAH O00519 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8407962 1.00 GPR84 (0.43) GPR84SPHK1FFAR1LMNAMAPT
SCHEMBL28219342 1.00 GPR84 (0.43) GPR84SPHK1FFAR1LMNAMAPT
SCHEMBL11554779 1.00 GPR84 (0.43) GPR84SPHK1FFAR1LMNAMAPT
SCHEMBL21066248 0.98 GPR84 (0.40) GPR84SPHK1FFAR1LMNAMAPT
SCHEMBL9408555 0.90 GPR84 (0.39) GPR84SPHK1FFAR1LMNAMAPT
SCHEMBL9408559 0.90 GPR84 (0.39) GPR84SPHK1FFAR1LMNAMAPT
SCHEMBL22116285 0.88 GPR84 (0.38) GPR84SPHK1FFAR1LMNAMAPT
SCHEMBL7539369 0.86 GPR84 (0.37) GPR84SPHK1FFAR1LMNAMAPT
SCHEMBL4840528 0.86 GPR84 (0.37) GPR84SPHK1FFAR1LMNAMAPT
SCHEMBL7547415 0.86 GPR84 (0.37) GPR84SPHK1FFAR1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4700017-A2 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES Acuitas Therapeutics Inc. (CA) 2026-02-25 EP disclosed
EP-4448486-B1 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES ACUITAS THERAPEUTICS INC (CA) 2025-10-15 EP disclosed
US-20250092002-A1 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES ACUITAS THERAPEUTICS INC (CA) 2025-03-20 US disclosed
US-20250059131-A1 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES ACUITAS THERAPEUTICS INC (CA) 2025-02-20 US disclosed
EP-4448486-A1 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES Acuitas Therapeutics, Inc. (CA) 2024-10-23 EP disclosed
EP-4448482-A2 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES Acuitas Therapeutics, Inc. (CA) 2024-10-23 EP disclosed
WO-2023114944-A1 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES Acuitas Therapeutics, Inc. (CA) 2023-06-22 WO disclosed
WO-2023114944-A1 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES Acuitas Therapeutics, Inc. (CA) 2023-06-22 WO disclosed
WO-2023114937-A2 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES Acuitas Therapeutics, Inc. (CA) 2023-06-22 WO disclosed
WO-2023114937-A2 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES Acuitas Therapeutics, Inc. (CA) 2023-06-22 WO disclosed
US-10295487-B2 In situ NMR parameter monitoring systems and methods for measuring pH and temperature THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2019-05-21 US disclosed
US-10067079-B2 Solid state NMR spectroscopy/imaging in situ measuring devices and methods for calibration and determining one or more quantitative properties of a target sample THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2018-09-04 US disclosed
WO-2017083665-A1 SOLID STATE NMR SPECTROSCOPY/IMAGING IN SITU MEASURING DEVICES THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2017-05-18 WO disclosed
US-20160109390-A1 In Situ NMR Parameter Monitoring Systems and Methods for Measuring PH and Temperature THE CURATORS OF THE UNIVERSITY OF MISSOURI 2016-04-21 US disclosed
US-20160109391-A1 SOLID STATE NMR SPECTROSCOPY/IMAGING IN SITU MEASURING DEVICES AND METHODS FOR CALIBRATION AND DETERMINING ONE OR MORE QUANTITATIVE PROPERTIES OF A TARGET SAMPLE THE CURATORS OF THE UNIVERSITY OF MISSOURI 2016-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059131-A1 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES PHOSPHO1, NPC1, SGMS1 GPR84 2773/4885SPHK1 322/4885FFAR1 82/4885
US-20250092002-A1 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES PHOSPHO1, LPAR3, RFTN1 GPR84 1519/4885SPHK1 476/4885FFAR1 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.